nur für Forschungszwecke

Curcumin p300/CBP Inhibitor

Name: Curcumin
Brand: Selleck Chemicals
SKU: S1848
Rating: 5 (50 reviews)

Kat.-Nr.S1848

Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) ist das Hauptcurcuminoid des beliebten indischen Gewürzs Kurkuma, das zur Ingwerfamilie (Zingiberaceae) gehört. Es ist ein Inhibitor der p300 histone acetylatransferase (IC50~25 μM) und der Histone deacetylase (HDAC); aktiviert den Nrf2 pathway und unterdrückt die Aktivierung von NF-κB. Curcumin induziert mitophagy, autophagy, apoptosis und Zellzyklusarrest mit Antitumoraktivität. Curcumin reduziert Nierenschäden, die mit Rhabdomyolyse verbunden sind, indem es den Ferroptosis-vermittelten Zelltod verringert. Curcumin zeigt antiinfektiöse Eigenschaften gegen verschiedene menschliche Pathogene wie den Influenza Virus, Hepatitis C Virus, HIV und so weiter.

Curcumin p300/CBP Inhibitor Chemical Structure

Chemische Struktur

Molekulargewicht: 368.38

Springe zu

Qualitätskontrolle

Charge: Reinheit: 99.94%

99.94

Verwandte Ziele	HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK
Weitere p300/CBP Inhibitoren	Inobrodib (CCS-1477) A-485 SGC-CBP30 Anacardic Acid CPI-637 E7386 I-CBP112 Histone Acetyltransferase Inhibitor II TTK21 GNE-049

Zellkultur, Behandlung & Arbeitskonzentration

Zelllinien	Assay-Typ	Konzentration	Inkubationszeit	Aktivitätsbeschreibung	PMID
U87	Cell viability assay	0, 10, 20, 30, 40, and 50 µM/L	24 hours	At concentrations higher than 20 µM/L, cell viabilities steeply declined	31062527
HEL cells	Cell viability assay	0-30 µmol/L	24/48 hours	The viability of the HEL cells exposed to curcumin was significantly lower compared to control cells even at low concentrations.	31033209
Raw246.7	Cell viability assay	1, 5, 10, 50, 100, 200, and 500 g/mL			31007701
RT112	Cell viability assay	0.1 or 0.4 μg/ml	24, 48, and 72 h	Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.4 μg/ml, each compared to respective controls	30984278
UMUC3	Cell viability assay	0.1 or 0.4 μg/ml	24, 48, and 73 h	Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.5 μg/ml, each compared to respective controls	30984278
TCCSUP	Cell viability assay	0.1 or 0.4 μg/ml	24, 48, and 74 h	Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.6 μg/ml, each compared to respective controls	30984278
KBM5	Antiproliferative assay		72 hrs	Antiproliferative activity against human KBM5 cells after 72 hrs by MTT assay, IC50 = 3.84 μM.	24280069
Jurkat	Antiproliferative assay		72 hrs	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay, IC50 = 4.29 μM.	24280069
U266	Antiproliferative assay		72 hrs	Antiproliferative activity against human U266 cells after 72 hrs by MTT assay, IC50 = 7.57 μM.	24280069
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 17.3 μM.	24280069
MCF7	Cytotoxicity assay		24 hrs	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay, IC50 = 32.2 μM.	26174555
SKOV3	Cytotoxicity assay		24 hrs	Cytotoxicity against human SKOV3 cells after 24 hrs by MTT assay, IC50 = 43.63 μM.	26174555
CT26	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 7.7 μM.	26318057
SW620	Cytotoxicity assay		72 hrs	Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 12.52 μM.	26318057
SGC7901	Cytotoxicity assay		72 hrs	Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 24.41 μM.	26318057
GES-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human GES-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 27.89 μM.	26318057
MGC803	Cytotoxicity assay		72 hrs	Cytotoxicity against human MGC803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 31.39 μM.	26318057
Caco2	Antiproliferative assay			Antiproliferative activity against human Caco2 cells, IC50 = 10.3 μM.	26539626
U2OS	Cytotoxicity assay		48 hrs	Cytotoxicity against human U2OS cells expressing wild-type p53 after 48 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 22.8 μM.	26606246
Saos2	Cytotoxicity assay		48 hrs	Cytotoxicity against human Saos2 cells expressing p53 mutant after 48 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 28.1 μM.	26606246
U2OS	Cytotoxicity assay		24 hrs	Cytotoxicity against human U2OS cells expressing wild-type p53 after 24 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 34.4 μM.	26606246
Saos2	Cytotoxicity assay		24 hrs	Cytotoxicity against human Saos2 cells expressing p53 mutant after 24 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 48.6 μM.	26606246
T98G	Antiproliferative assay		24 hrs	Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay, IC50 = 10 μM.	26631318
T98G	Antiproliferative assay		72 hrs	Antiproliferative activity against human T98G cells assessed as cell viability after 72 hrs by MTT assay, IC50 = 25 μM.	26631318
T67	Neuroprotective assay			Neuroprotective effect in human T67 cells assessed as increase in NQO1 activity using DCIP as substrate	26696252
SH-SY5Y	Antiproliferative assay		48 hrs	Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 48 hrs, IC50 = 16.1 μM.	26705144
HeLa	Antiproliferative assay		48 hrs	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs, IC50 = 21.8 μM.	26705144
HeLa	Cell cycle assay		16 hrs	Cell cycle arrest in human HeLa cells assessed as accumulation at G1 phase at IC50 to 2 times IC50 after 16 hrs by FACS analysis	26705144
HuH7	Cytotoxicity assay		48 hrs	Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay, IC50 = 48 μM.	26783179
HeLa	Antiproliferative assay		3 days	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 12.11 μM.	26827161
LNCAP	Antiproliferative assay		3 days	Antiproliferative activity against human LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 13.61 μM.	26827161
PC3	Antiproliferative assay		3 days	Antiproliferative activity against human PC3 cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 25.43 μM.	26827161
DU145	Antiproliferative assay		3 days	Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 26.23 μM.	26827161
RAW264.7	Antiinflammatory assay		24 hrs	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50 = 19.1 μM.	26841168
BV2	Function assay		24 hrs	Inhibition of LPS-induced NO production in mouse BV2 cells assessed as reduction in nitrite level pretreated for 24 hrs before LPS treatment for additional 24 hrs by Griess reaction method, IC50 = 0.52 μM.	26859776
HepG2	Cytotoxicity assay			Cytotoxicity activity against human HepG2 cells by MTT assay, IC50 = 4.43 μM.	26873414
A549	Cytotoxicity assay			Cytotoxicity against human A549 cells by MTT assay, IC50 = 23.54 μM.	26873414
MCF7	Cytotoxicity assay			Cytotoxicity against human MCF7 cells by MTT assay, IC50 = 46.25 μM.	26873414
SKOV3	Cytotoxicity assay			Cytotoxicity against human SKOV3 cells by MTT assay, IC50 = 49.85 μM.	26873414
A549/CDDP	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay, IC50 = 32.39 μM.	26891099
A549	Antiproliferative assay		72 hrs	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 38.12 μM.	26891099
A549/CDDP	Function assay			Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry, IC50 = 39.42 μM.	26891099
A549	Function assay			Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry, IC50 = 40.56 μM.	26891099
A549	Apoptosis assay	2.1 to 4.2 uM	24 hrs	Induction of apoptosis in human A549 cells at 2.1 to 4.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry	26891099
A549/CDDP	Apoptosis assay	0.6 to 1.2 uM	24 hrs	Induction of apoptosis in human A549/CDDP cells at 0.6 to 1.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry	26891099
bone marrow	Function assay		48 hrs	Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay, IC50 = 7.5 μM.	26923696
U937	Function assay		17 to 20 hrs	Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay, IC50 = 1.88 μM.	27040659
RAW264.7	Function assay		17 to 20 hrs	Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay, IC50 = 15.95 μM.	27040659
BV2	Antiinflammatory assay		24 hrs	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50 = 4.77 μM.	27228227
SH-SY5Y	Neuroprotective assay		24 hrs	Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay, EC50 = 6.2 μM.	27420919
PC3	Cytotoxicity assay		24 hrs	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 39 μM.	27496212
DU145	Cytotoxicity assay		24 hrs	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 41 μM.	27496212
4T1	Cytotoxicity assay		24 hrs	Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 49.4 μM.	27496212
T47D	Cytotoxicity assay		24 hrs	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 30 μM.	27517806
CHOK1	Growth inhibition assay		72 hrs	Growth inhibition of CHOK1 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay, IC50 = 7.5 μM.	27521589
LNCAP	Antiproliferative assay		3 days	Antiproliferative activity against human LNCAP cells after 3 days by WST or trypan blue assay, IC50 = 13.61 μM.	27543391
PC3	Antiproliferative assay		3 days	Antiproliferative activity against human PC3 cells after 3 days by WST or trypan blue assay, IC50 = 25.43 μM.	27543391
DU145	Antiproliferative assay		3 days	Antiproliferative activity against human DU145 cells after 3 days by WST or trypan blue assay, IC50 = 26.23 μM.	27543391
BV2	Function assay		1 hr	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 1 hr before LPS stimulation measured after 24 hrs by Griess assay, IC50 = 1.42 μM.	27592135
BV2	Function assay		1 hr	Inhibition of Src in mouse BV2 cells assessed as suppression of LPS-induced NO release preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay, IC50 = 2.2 μM.	27617803
A549	Antiproliferative assay		48 hrs	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, IC50 = 15.06 μM.	27816267
MDA-MB-231	Antiproliferative assay		48 hrs	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 24.54 μM.	27816267
DU145	Antiproliferative assay		48 hrs	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 44.71 μM.	27816267
EAhy926	Cytotoxicity assay		48 hrs	Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 24.6 μM.	27843113
Caco2	Cytotoxicity assay		48 hrs	Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 38.3 μM.	27843113
CHOK1	Cytotoxicity assay		48 hrs	Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 42 μM.	27843113
SH-SY5Y	Function assay	1 to 5 uM	24 hrs	Antioxidant activity against t-BHP-induced oxidative stress in human SH-SY5Y cells assessed as inhibition of ROS production at 1 to 5 uM after 24 hrs by DCFH-DA probe based flow cytometric analysis	27856236
NCI-H1650	Cytotoxicity assay		72 hrs	Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay, IC50 = 20.7 μM.	27886548
LLC	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay, IC50 = 24.7 μM.	27886548
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay, IC50 = 27.8 μM.	27886548
K562	Function assay		48 hrs	Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay, GI50 = 19.67 μM.	27908756
K562	Antiproliferative assay		48 hrs	Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay, GI50 = 21.67 μM.	27908756
H460	Function assay		48 hrs	Inhibition of P-gp in drug resistant human H460 cells assessed as reduction in cell viability measured after 48 hrs by sulforhodamine B assay, GI50 = 26 μM.	27908756
NCI-H460	Antiproliferative assay		48 hrs	Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay, GI50 = 27.3 μM.	27908756
K562	Function assay	20 to 30 uM	48 hrs	Down regulation of p-gp expression in doxorubicin resistant human K562 cells at 20 to 30 uM measured after 48 hrs by Western blot method	27908756
K562	Cell cycle assay	20 uM	48 hrs	Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in G0/G1 phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry	27908756
K562	Cell cycle assay	20 uM	48 hrs	Cell cycle arrest in doxorubicin resistant human K562 cells assessed as increase in G2/M phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry	27908756
K562	Function assay	20 to 40 uM	48 hrs	Up regulation of p53 expression in doxorubicin resistant human K562 cells at 20 to 40 uM measured after 48 hrs by Western blot method	27908756
K562	Cell cycle assay	20 uM	48 hrs	Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in S phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry	27908756
K562	Cell cycle assay	30 to 40 uM	48 hrs	Cell cycle arrest in doxorubicin resistant human K562 cells assessed as accumulation at G0/G1 phase at 30 to 40 uM measured after 48 hrs by propidium iodide staining based flow cytometry	27908756
K562	Cell cycle assay	30 to 40 uM	48 hrs	Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in G2/M phase at 30 to 40 uM measured after 48 hrs by propidium iodide staining based flow cytometry	27908756
K562	Function assay	20 to 40 uM	48 hrs	Down regulation of cyclin B1 expression in doxorubicin resistant human K562 cells at 20 to 40 uM measured after 48 hrs by Western blot method	27908756
K562	Apoptosis assay	20 to 40 uM	48 hrs	Induction of apoptosis in doxorubicin resistant human K562 cells decrease in pro-caspase 3 level at 20 to 40 uM measured after 48 hrs by Western blot method	27908756
K562	Apoptosis assay	20 to 40 uM	48 hrs	Induction of apoptosis in doxorubicin resistant human K562 cells assessed as increase in PARP-1 cleavage at 20 to 40 uM measured after 48 hrs by Western blot method	27908756
Raji	Function assay		48 hrs	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48 hrs by indirect immunofluorescence method, IC50 = 12.1 μM.	27933896
BV2	Function assay		24 hrs	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 24 hrs followed by LPS-stimulation after 24 hrs by Griess assay, IC50 = 2.36 μM.	28032759
PC3	Antiproliferative assay		48 hrs	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 12.22 μM.	28038323
MDA-MB-231	Antiproliferative assay		48 hrs	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 15.81 μM.	28038323
BT549	Antiproliferative assay		48 hrs	Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay, IC50 = 24.93 μM.	28038323
HeLa	Antiproliferative assay		48 hrs	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 25.41 μM.	28038323
DU145	Antiproliferative assay		48 hrs	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 28.41 μM.	28038323
BV2	Function assay		30 mins	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay, IC50 = 4.5 μM.	28055210
THP1	Function assay		1 hr	Inhibition of LPS-induced tissue factor procoagulant activity in human THP1 cells preincubated for 1 hr followed by LPS addition measured after 5 hrs using factor 10a chromogenic substrate in presence of prothrombin complex, IC50 = 0.01316 μM.	28109788
RAW264.7	Antiinflammatory assay	20 uM		Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production at 20 uM by ELISA	28284806
RAW264.7	Antiinflammatory assay	20 uM		Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 20 uM by ELISA	28284806
PC12	Neuroprotective assay	0.1 to 10 uM	24 hrs	Neuroprotective activity against H202-induced toxicity in rat PC12 cells assessed as increase in cell viability at 0.1 to 10 uM after 24 hrs by MTT assay	28302511
PC12	Neuroprotective assay	0.1 to 10 uM	24 hrs	Neuroprotective activity against Abeta42-induced toxicity in rat PC12 cells assessed as increase in cell viability at 0.1 to 10 uM after 24 hrs by MTT assay	28302511
HCT116	Antiproliferative assay			Antiproliferative activity against human HCT116 cells up to 72 hrs by MTT assay, IC50 = 13.77 μM.	28319780
MDA-MB-231	Antiproliferative assay			Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay, IC50 = 16.23 μM.	28319780
PC3	Antiproliferative assay			Antiproliferative activity against human PC3 cells up to 72 hrs by MTT assay, IC50 = 18.8 μM.	28319780
BT474	Antiproliferative assay		24 hrs	Antiproliferative activity against HER2 positive human BT474 cells after 24 hrs by MTT assay, IC50 = 30.14 μM.	28319780
MDA-MB-453	Antiproliferative assay		24 hrs	Antiproliferative activity against HER2 positive human MDA-MB-453 cells after 24 hrs by MTT assay, IC50 = 32.4 μM.	28319780
MDA-MB-157	Antiproliferative assay		24 hrs	Antiproliferative activity against human MDA-MB-157 cells after 24 hrs by MTT assay, IC50 = 40.38 μM.	28319780
SKBR3	Antiproliferative assay		24 hrs	Antiproliferative activity against HER2 positive human SKBR3 cells after 24 hrs by MTT assay, IC50 = 42.83 μM.	28319780
MCF7	Antiproliferative assay		24 hrs	Antiproliferative activity against ER/PR positive human MCF7 cells after 24 hrs by MTT assay, IC50 = 42.89 μM.	28319780
MDA-MB-468	Antiproliferative assay		24 hrs	Antiproliferative activity against human MDA-MB-468 cells after 24 hrs by MTT assay, IC50 = 42.89 μM.	28319780
T47D	Antiproliferative assay		24 hrs	Antiproliferative activity against ER/PR positive human T47D cells after 24 hrs by MTT assay, IC50 = 47.91 μM.	28319780
cells at	Growth inhibition assay	30 uM	48 hrs	Growth inhibition of human Hep3B cells at 30 uM after 48 hrs by MTT assay	28342400
PWR-1E	Antiproliferative assay		3 days	Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay, IC50 = 8.14 μM.	28388523
LNCAP	Antiproliferative assay		3 days	Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay, IC50 = 13.61 μM.	28388523
PC3	Antiproliferative assay		3 days	Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay, IC50 = 25.43 μM.	28388523
DU145	Antiproliferative assay		3 days	Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay, IC50 = 26.23 μM.	28388523
HepG2	Function assay	5 uM	24 hrs	Activation of Nrf2 in human HepG2 cells assessed as cytoprotection against t-BHP-induced oxidative cell death at 5 uM incubated for 24 hrs followed by compound removal with subsequent incubation with 900 uM of t-BHP for 6 hrs by MTT assay	28399452
BV2	Antineuroinflammatory assay		15 mins	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 15 mins followed by LPS-stimulation measured after 24 hrs by colorimetric method, IC50 = 6 μM.	28514148
L428	Function assay		2 hrs	Inhibition of NF-kappaB (unknown origin) expressed in human L428 cells after 2 hrs by luciferase reporter gene assay	28526369
PWR-1E	Antiproliferative assay		3 days	Antiproliferative activity against human PWR-1E cells expressing androgen receptor and PSA assessed as decrease in cell viability after 3 days by WST assay, IC50 = 8.85 μM.	28601720
LNCAP	Antiproliferative assay		3 days	Antiproliferative activity against human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 13.61 μM.	28601720
PC3	Antiproliferative assay		3 days	Antiproliferative activity against human PC3 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 25.43 μM.	28601720
DU145	Antiproliferative assay		3 days	Antiproliferative activity against human DU145 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 26.23 μM.	28601720
MDA-MB-231	Cytotoxicity assay		48 hrs	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 12 μM.	28654265
HT-29	Cytotoxicity assay		48 hrs	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 14 μM.	28654265
NCI-H460	Cytotoxicity assay		48 hrs	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 15 μM.	28654265
LN229	Cytotoxicity assay		48 hrs	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 15 μM.	28654265
U87	Cytotoxicity assay		48 hrs	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 16 μM.	28654265
COLO201	Cytotoxicity assay		48 hrs	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 18 μM.	28654265
A549	Cytotoxicity assay		48 hrs	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 18 μM.	28654265
T47D	Cytotoxicity assay		48 hrs	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 19 μM.	28654265
MML1	Cytotoxicity assay		48 hrs	Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 19 μM.	28654265
BxPC3	Cytotoxicity assay		48 hrs	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 29 μM.	28654265
SK-MEL-2	Cytotoxicity assay		48 hrs	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 36 μM.	28654265
HCT116	Antiproliferative assay		48 hrs	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay, GI50 = 3.5 μM.	28716495
HCT116	Function assay		48 hrs	Induction of mitochondrial membrane potential loss in human HCT116 cells at antiproliferative GI50 after 48 hrs by JC-1 staining based fluorescence assay	28716495
HCT116	Function assay		60 mins	Induction of mitochondrial superoxide generation in human HCT116 cells at antiproliferative GI50 after 60 mins by mitoSOX red-probe based fluorescence assay	28716495
HCT116	Function assay		60 mins	Induction of reactive oxygen species generation in human HCT116 cells at antiproliferative GI50 after 60 mins by DCFH-DA probe based assay	28716495
HCT116	Function assay	500 uM	48 hrs	Induction of glutathione oxidation in human HCT116 cells assessed as increase in GSSG/GSH ratio at 500 uM in presence of NADPH after 48 hrs by Ellman's method	28716495
MCF7	Function assay		48 hrs	Modulation activity at ER in human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 48 μM.	28797797
A549	Growth inhibition assay			Growth inhibition of human A549 cells, IC50 = 23 μM.	28814374
BGC823	Growth inhibition assay	20 uM	72 hrs	Growth inhibition of human BGC823 cells at 20 uM after 72 hrs by MTT assay	28881286
SGC7901	Growth inhibition assay	20 uM	72 hrs	Growth inhibition of human SGC7901 cells at 20 uM after 72 hrs by MTT assay	28881286
MFC	Growth inhibition assay	20 uM	72 hrs	Growth inhibition of MFC cells at 20 uM after 72 hrs by MTT assay	28881286
BV2	Antiinflammatory assay		24 hrs	Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay, IC50 = 4 μM.	29035525
NCI-H460	Cytotoxicity assay		48 hrs	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 17.14 μM.	29174816
PC3	Cytotoxicity assay		48 hrs	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 18.71 μM.	29174816
DU145	Cytotoxicity assay		48 hrs	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 33.12 μM.	29174816
HepG2	Function assay		5 hrs	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay, EC50 = 21 μM.	29223100
BGC823	Cytotoxicity assay		72 hrs	Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 19.5 μM.	29288946
NCI-H460	Cytotoxicity assay		72 hrs	Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 20.3 μM.	29288946
SGC7901	Cytotoxicity assay		72 hrs	Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 26.2 μM.	29288946
NCI-H460	Growth inhibition assay	5 to 10 uM	24 to 72 hrs	Growth inhibition of human NCI-H460 cells assessed as reduction in cell viability at 5 to 10 uM incubated for 24 to 72 hrs by MTT assay	29288946
NCI-H460	Growth inhibition assay	20 uM	18 hrs	Anti-growth activity against human NCI-H460 cells assessed as reduction in colony formation at 20 uM after 18 hrs by crystal violet-based colony forming assay	29288946
NCI-H460	Antimigratory assay	20 uM	48 hrs	Anti-migratory activity against human NCI-H460 cells at 20 uM incubated for 48 hrs by wound healing assay	29288946
NCI-H460	Apoptosis assay	15 mg/kg	15 days	Induction of apoptosis in tumor of human NCI-H460 cells xenografted in BALB/C nu nude mouse assessed as downregulation of bcl2 expression at 15 mg/kg, ip administered everyday for 15 days by Western blot analysis	29288946
HepG2	Cytotoxicity assay		24 hrs	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 13.78 μM.	29421568
THP1	Cytotoxicity assay		24 hrs	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 22.54 μM.	29421568
K562	Cytotoxicity assay		24 hrs	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 23.12 μM.	29421568
LO2	Cytotoxicity assay		24 hrs	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 25.67 μM.	29421568
HeLa	Cytotoxicity assay		24 hrs	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 31.89 μM.	29421568
NCI-H460	Cytotoxicity assay		48 hrs	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 17.11 μM.	29429834
PC3	Cytotoxicity assay		48 hrs	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 18.65 μM.	29429834
DU145	Cytotoxicity assay		48 hrs	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 33.15 μM.	29429834
MCF7	Cytotoxicity assay		4 hrs	Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 22.1 μM.	29605808
WRL68	Cytotoxicity assay		4 hrs	Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 27.8 μM.	29605808
A549	Cytotoxicity assay		4 hrs	Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 43.9 μM.	29605808
NCI-H1975	Cytotoxicity assay		72 hrs	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 1.4 μM.	29655083
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 6.8 μM.	29655083
HL7702	Cytotoxicity assay		72 hrs	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 7.2 μM.	29655083
H460	Cytotoxicity assay		72 hrs	Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 8.5 μM.	29655083
NCI-H1650	Cytotoxicity assay		72 hrs	Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 20.5 μM.	29655083
HepG2	Cytotoxicity assay		24 hrs	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 10 μM.	29798827
HCT116	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 10.91 μM.	29886021
HepG2	Cytotoxicity assay		24 hrs	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 16.01 μM.	29909338
SMMC7721	Cytotoxicity assay		24 hrs	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 19.47 μM.	29909338
QGY7703	Cytotoxicity assay		24 hrs	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 21.44 μM.	29909338
HHL5	Cytotoxicity assay		24 hrs	Cytotoxicity against human HHL5 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 22.27 μM.	29909338
LO2	Cytotoxicity assay		24 hrs	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 23.87 μM.	29909338
Vero	Cytotoxicity assay			Cytotoxicity against African green monkey Vero cells assessed as growth inhibition, CC50 = 36.8 μM.	29920454
HT22	Cytotoxicity assay		24 hrs	Cytotoxicity against mouse HT22 cells assessed as reduction in cell viability after 24 hrs by MTT assay, MNTD = 1 μM.	30031653
HT22	Cytoprotection assay	1 uM	24 hrs	Cytoprotection against glutamate-induced apoptosis in mouse HT22 cells assessed as decrease in Bax/Bcl2 ratio at 1 uM after 24 hrs by RT-PCR method	30031653
HT22	Cytoprotection assay	1 uM	24 hrs	Cytoprotection against glutamate-induced oxidative stress in mouse HT22 cells assessed as decrease in iNOS mRNA level at 1 uM after 24 hrs by RT-PCR method	30031653
HT22	Cytoprotection assay	1 uM	24 hrs	Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as increase in cell viability at 1 uM after 24 hrs by optical microscopic assay	30031653
HT22	Cytoprotection assay	1 uM	24 hrs	Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as decrease in glutamate-induced cell cycle arrest at sub-G1 phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry	30031653
HT22	Cytoprotection assay	1 uM	24 hrs	Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as increase in cell proliferation at 1 uM after 24 hrs by MTT assay	30031653
LNCAP	Antiproliferative assay			Antiproliferative activity against androgen-sensitive human LNCAP cells, IC50 = 2 μM.	30121214
DU145	Antiproliferative assay			Antiproliferative activity against androgen-insensitive human DU145 cells, IC50 = 2 μM.	30121214
PC3	Antiproliferative assay			Antiproliferative activity against androgen-insensitive human PC3 cells, IC50 = 2 μM.	30121214
LNCAP	Antiproliferative assay		3 days	Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 13.61 μM.	30121214
PC3	Antiproliferative assay		3 days	Antiproliferative activity against androgen-insensitive human PC3 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 25.43 μM.	30121214
DU145	Antiproliferative assay		3 days	Antiproliferative activity against androgen-insensitive human DU145 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 26.23 μM.	30121214
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 9.8 μM.	30138803
EJ28	Cytotoxicity assay		72 hrs	Cytotoxicity against human EJ28 cells after 72 hrs by MTT assay, IC50 = 10.5 μM.	30138803
HT1080	Cytotoxicity assay		72 hrs	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay, IC50 = 13.1 μM.	30138803
SW620	Cytotoxicity assay		72 hrs	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay, IC50 = 14 μM.	30138803
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 17.9 μM.	30138803
SMMC7721	Cytotoxicity assay		24 hrs	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 16.68 μM.	30771605
HepG2	Cytotoxicity assay		24 hrs	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 17.37 μM.	30771605
LO2	Cytotoxicity assay		24 hrs	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 22.69 μM.	30771605
QGY7703	Cytotoxicity assay		24 hrs	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 23.91 μM.	30771605
HHL5	Cytotoxicity assay		24 hrs	Cytotoxicity against human HHL5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 24.19 μM.	30771605
HCT-116	Function assay		24 hrs	Inhibition of chymotrypsin-like activity of human 26S proteasome in human HCT-116 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometr, IC50 = 10 μM.	30776692
SW480	Function assay		24 hrs	Inhibition of chymotrypsin-like activity of human 26S proteasome in human SW480 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometric, IC50 = 10 μM.	30776692
RAW264.7	Function assay	10 uM	0.5 hrs	Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha production at 10 uM pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA relative to control	30780088
RAW264.7	Function assay		0.5 hrs	Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha production pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA	30780088
RAW264.7	Function assay		0.5 hrs	Inhibition of LPS-induced NFkappaB p65 nuclear translocation in ICR mouse RAW264.7 cells preincubated for 0.5 hrs followed by LPS challenge and measured after 40 mins by DAPI staining-based immunofluorescence microscopic analysis	30780088
RAW264.7	Function assay	10 uM	0.5 hrs	Inhibition of LPS-induced p38 MAPK phosphorylation in ICR mouse RAW264.7 cells at 10 uM preincubated for 0.5 hrs followed by LPS challenge and measured after 30 mins by immunoblotting analysis	30780088
RAW264.7	Function assay	10 uM	0.5 hrs	Inhibition of LPS-induced ERK phosphorylation in ICR mouse RAW264.7 cells at 10 uM preincubated for 0.5 hrs followed by LPS challenge and measured after 30 mins by immunoblotting analysis	30780088
RAW264.7	Function assay	10 uM	0.5 hrs	Inhibition of NFkappaB/MAPK signaling in LPS-induced mouse RAW264.7 cells assessed as down regulation of IkappaB expression at 10 uM preincubated for 0.5 hrs followed by LPS-challenge and measured after 30 mins by immunoblotting analysis	30780088
RAW264.7	Function assay	10 uM	0.5 hrs	Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 production at 10 uM pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA relative to control	30780088
RAW264.7	Function assay		0.5 hrs	Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 production pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA	30780088
RAW264.7	Function assay		4 hrs	Inhibition of RANKL-induced osteoclastogenesis in murine RAW264.7 cells assessed as formation of TRAP positive multinucleated osteoclasts pretreated for 4 hrs followed by RANKL addition measured after 72 hrs, IC50 = 3 μM.	30794412
BV2	Antineuroinflammatory assay		1 hr	Anti-neuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess reagent based assay, IC50 = 1.58 μM.	31005056
HeLa	Anticancer assay			Anticancer activity against human HeLa cells, IC50 = 4.33 μM.	31129455
HL60	Cytotoxicity assay			Cytotoxicity against human HL60 cells, IC50 = 6.3 μM.	31129455
SKOV3	Cytotoxicity assay		48 hrs	Cytotoxicity against human SKOV3 Cells after 48 hrs by Cell Titer Blue assay, IC50 = 6.7 μM.	31129455
HSC4	Cytotoxicity assay			Cytotoxicity against human HSC4 cells, IC50 = 7.1 μM.	31129455
U87MG	Cytotoxicity assay		48 hrs	Cytotoxicity against human U87MG Cells 48 hrs by MTS assay, IC50 = 7.15 μM.	31129455
HSC2	Cytotoxicity assay			Cytotoxicity against human HSC2 cells, IC50 = 7.8 μM.	31129455
LX2	Cytotoxicity assay		48 hrs	Cytotoxicity against human LX2 Cells after 48 hrs by MTT assay, IC50 = 9.14 μM.	31129455
MCF7	Cytotoxicity assay		48 hrs	Cytotoxicity against human MCF7 Cells after 48 hrs by MTT assay, IC50 = 9.28 μM.	31129455
HepG2	Cytotoxicity assay		48 hrs	Cytotoxicity against human HepG2 Cells after 48 hrs by MTT assay, IC50 = 9.44 μM.	31129455
3T3	Cytotoxicity assay		48 hrs	Cytotoxicity against mouse 3T3 Cells after 48 hrs by MTT assay, IC50 = 9.51 μM.	31129455
AGS	Cytotoxicity assay			Cytotoxicity against human AGS Cells, IC50 = 9.77 μM.	31129455
HSC3	Cytotoxicity assay			Cytotoxicity against human HSC3 cells, IC50 = 11 μM.	31129455
MDA-MB-231	Anticancer assay		72 hrs	Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 11.45 μM.	31129455
SMMC7721	Anticancer assay		72 hrs	Anticancer activity against human SMMC7721 cells after 72 hrs by MTT assay, IC50 = 12.57 μM.	31129455
LX2	Anticancer assay		72 hrs	Anticancer activity against human LX2 cells after 72 hrs by MTT assay, IC50 = 13.97 μM.	31129455
HeLa	Cytotoxicity assay			Cytotoxicity against human HeLa Cells, IC50 = 14.03 μM.	31129455
SW480	Cytotoxicity assay		24 to 48 hrs	Cytotoxicity against human SW480 Cells after 24 to 48 hrs by MTT assay, IC50 = 15 μM.	31129455
U251MG	Cytotoxicity assay		48 hrs	Cytotoxicity against human U251MG cells after 48 hrs by MTS assay, IC50 = 15.26 μM.	31129455
RWPE1	Cytotoxicity assay			Cytotoxicity against human RWPE1 cells, IC50 = 15.62 μM.	31129455
MCF7	Apoptosis assay			Induction of apoptosis in human MCF7 cells, IC50 = 17.1 μM.	31129455
BGC823	Cytotoxicity assay			Cytotoxicity against human BGC823 cells, IC50 = 17.5 μM.	31129455
BxPC3	Cytotoxicity assay			Cytotoxicity against human BxPC3 cells, IC50 = 18.25 μM.	31129455
HT-29	Cytotoxicity assay			Cytotoxicity against human HT-29 Cells, IC50 = 18.74 μM.	31129455
H1299	Cytotoxicity assay			Cytotoxicity against human H1299 cells, IC50 = 18.93 μM.	31129455
PC3	Cytotoxicity assay			Cytotoxicity against human PC3 cells, IC50 = 19.98 μM.	31129455
EAhy926	Cytotoxicity assay		72 hrs	Cytotoxicity against human EAhy926 Cells after 72 hrs by MTT assay, IC50 = 20 μM.	31129455
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 Cells after 72 hrs by MTT assay, IC50 = 20.3 μM.	31129455
AGS	Cytotoxicity assay			Cytotoxicity against human AGS Cells by MTT assay, IC50 = 20.76 μM.	31129455
PC3	Anticancer assay			Anticancer activity against human PC3 cells, IC50 = 20.9 μM.	31129455
MGC803	Cytotoxicity assay			Cytotoxicity against human MGC803 cells, IC50 = 21.2 μM.	31129455
CHOK1	Cytotoxicity assay		72 hrs	Cytotoxicity against human CHOK1 Cells after 72 hrs by MTT assay, IC50 = 21.3 μM.	31129455
Hep2	Cytotoxicity assay			Cytotoxicity against human Hep2 Cells, IC50 = 21.37 μM.	31129455
MCF7	Cytotoxicity assay			Cytotoxicity against human MCF7 cells, IC50 = 22.5 μM.	31129455
SGC7901	Cytotoxicity assay			Cytotoxicity against human SGC7901 cells, IC50 = 22.5 μM.	31129455
HT-29	Cytotoxicity assay		72 hrs	Cytotoxicity against human HT-29 Cells after 72 hrs by MTT assay, IC50 = 23.4 μM.	31129455
A549	Cytotoxicity assay			Cytotoxicity against human A549 Cells by MTT assay, IC50 = 25.33 μM.	31129455
MDA-MB-231	Cytotoxicity assay			Cytotoxicity against human MDA-MB-231 cells, IC50 = 26.5 μM.	31129455
A549	Cytotoxicity assay		24 to 48 hrs	Cytotoxicity against human A549 Cells after 24 to 48 hrs by MTT assay, IC50 = 28 μM.	31129455
Caco2	Cytotoxicity assay		72 hrs	Cytotoxicity against human Caco2 Cells after 72 hrs by MTT assay, IC50 = 28 μM.	31129455
GES-1	Cytotoxicity assay			Cytotoxicity against human GES-1 cells, IC50 = 29.1 μM.	31129455
DU145	Anticancer assay			Anticancer activity against human DU145 cells, IC50 = 31.7 μM.	31129455
MDCK2	Cytotoxicity assay		15 mins	Cytotoxicity against mitoxantrone resistant human MDCK2 cells expressing BCRP after 15 mins by fluorescence assay, IC50 = 32 μM.	31129455
HL-7702	Cytotoxicity assay			Cytotoxicity against human HL-7702 cells, IC50 = 32.33 μM.	31129455
K562	Cytotoxicity assay		24 to 48 hrs	Cytotoxicity against human K562 Cells after 24 to 48 hrs by MTT assay, IC50 = 36 μM.	31129455
HepG2	Cytotoxicity assay			Cytotoxicity against human HepG2 Cells, IC50 = 36.77 μM.	31129455
GBM1	Cytotoxicity assay		48 hrs	Cytotoxicity against human GBM1 Cells 48 hrs by MTS assay, IC50 = 39.65 μM.	31129455
PC12	Cytotoxicity assay		24 hrs	Cytotoxicity against rat PC12 cells measured after 24 hrs by WST8/PMS assay, CC50 = 42 μM.	31262559
HCT116	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 10.5 μM.	31326241
HeLa	Cytotoxicity assay			Cytotoxicity against human HeLa cells, IC50 = 8.2 μM.	31336310
B16	Cytotoxicity assay			Cytotoxicity against human B16 cells by MTT assay, IC50 = 8.5 μM.	31336310
HT1080	Function assay			Decrease in UPA expression in human HT1080 cells, IC50 = 10 μM.	31336310
Hep3B	Cytotoxicity assay			Cytotoxicity against human Hep3B cells, IC50 = 10 μM.	31336310
BT474	Cytotoxicity assay			Cytotoxicity against human BT474 cells, IC50 = 11 μM.	31336310
T47D	Cytotoxicity assay			Cytotoxicity against human T47D cells, IC50 = 11 μM.	31336310
HaCaT	Cytotoxicity assay			Cytotoxicity against human HaCaT cells, IC50 = 13 μM.	31336310
KM12	Cytotoxicity assay		4 hrs	Cytotoxicity against human KM12 cells after 4 hrs by MTT assay, IC50 = 16 μM.	31336310
HPL1D	Cytotoxicity assay			Cytotoxicity against human HPL1D cells, IC50 = 16 μM.	31336310
SW480	Cytotoxicity assay		4 hrs	Cytotoxicity against human SW480 cells after 4 hrs by MTT assay, IC50 = 17.94 μM.	31336310
MCF7	Cytotoxicity assay			Cytotoxicity against human MCF7 cells, IC50 = 19.9 μM.	31336310
HT-29	Cytotoxicity assay		4 hrs	Cytotoxicity against human HT-29 cells after 4 hrs by MTT assay, IC50 = 20.73 μM.	31336310
WiDr	Cytotoxicity assay		4 hrs	Cytotoxicity against human WiDr cells after 4 hrs by MTT assay, IC50 = 26.82 μM.	31336310
SW116	Cytotoxicity assay		4 hrs	Cytotoxicity against human SW116 cells after 4 hrs by MTT assay, IC50 = 27.46 μM.	31336310
Colon 26	Cytotoxicity assay		4 hrs	Cytotoxicity against mouse Colon 26 cells after 4 hrs by MTT assay, IC50 = 30.34 μM.	31336310
22Rv1	Function assay			Inhibition of NFkappaB p65 nuclear translocation in human 22Rv1 cells at GI50 by DAPI staining based immunofluorescence assay	31767266
PC3	Antiproliferative assay		48 hrs	Antiproliferative activity human PC3 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay	31767266
22Rv1	Antiproliferative assay		48 hrs	Antiproliferative activity human 22Rv1 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay	31767266
PC3	Function assay			Inhibition of NFkappaB p65 nuclear translocation in human PC3 cells at GI50 by DAPI staining based immunofluorescence assay	31767266
PC3	Function assay			Inhibition of NFkappaB p65 transcriptional activity in human PC3 cells at GI50 by sandwich ELISA	31767266
22Rv1	Function assay			Inhibition of NFkappaB p65 transcriptional activity in human 22Rv1 cells at GI50 by sandwich ELISA	31767266
Sf21	Function assay		10 mins	Inhibition of recombinant human full-length His6-tagged p300 expressed in baculovirus infected Sf21 insect cells using [3H]acetylCoA as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by liquid scintillation co, IC50 = 25 μM.	31910017
COS7	Function assay		10 mins	Inhibition of rabbit SERCA1b expressed in COS7 cells microsomal membranes preincubated for 10 mins followed by addition of ATP and measured after 40 mins by ELISA method, Ki = 5.8 μM.	32030976
COS7	Function assay		10 mins	Inhibition of human SERCA3a expressed in COS7 cells microsomal membranes preincubated for 10 mins followed by addition of ATP and measured after 40 mins by ELISA method, Ki = 8.6 μM.	32030976
A549	Function assay		15 mins	Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis, IC50 = 0.2 μM.	ChEMBL
RAW264.7	Function assay		20 hrs	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by griess assay, IC50 = 0.8 μM.	ChEMBL
MDCK	Antiviral assay		40 hrs	Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 40 hrs by CellTiter-Glo assay, IC50 = 6.7 μM.	ChEMBL
MDCK	Antiviral assay		40 hrs	Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 40 hrs by CellTiter-Glo assay, IC50 = 6.7 μM.	ChEMBL
RAW264.7	Antiinflammatory assay		17 hrs	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFN-gamma-stimulated nitric oxide production after 17 hrs by Griess assay, IC50 = 14.7 μM.	ChEMBL
HEK293T	Cytotoxicity assay			Cytotoxicity against HEK293T cells, IC50 = 15.2 μM.	ChEMBL
J774.1	Cytotoxicity assay			Cytotoxicity against mouse J774.1 cells, IC50 = 31 μM.	ChEMBL
MDCK	Cytotoxicity assay		40 hrs	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay, CC50 = 48.3 μM.	ChEMBL
MDCK	Cytotoxicity assay		40 hrs	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 40 hrs by CellTiter-Glo assay, CC50 = 48.3 μM.	ChEMBL
3T3L1	Function assay	10 ng/ml		Inhibition of TNFalpha-induced NFkappaB activation (unknown origin) expressed in mouse 3T3L1 cells at 10 ng/ml by luciferase reporter gene assay	ChEMBL
Klicken Sie hier, um weitere experimentelle Daten zu Zelllinien anzuzeigen

Chemische Informationen, Lagerung & Stabilität

Molekulargewicht	368.38	Formel	C₂₁H₂₀O₆	Lagerung (Ab dem Eingangsdatum)	3 Jahre-20°CPulver
CAS-Nr.	458-37-7	SDF herunterladen		Lagerung von Stammlösungen	1 Jahr-80°Cin Lösungsmittel 1 Monat-20°Cin Lösungsmittel
Synonyme	Diferuloylmethane, Natural Yellow 3, Turmeric yellow			Smiles	COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O

Löslichkeit

In vitro
Charge:

DMSO : 250 mg/mL (678.64 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 73 mg/mL (198.16 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 73 mg/mL (198.16 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 73 mg/mL (198.16 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 74 mg/mL (200.87 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molaritätsrechner

Masse	Konzentration	Volumen	Molekulargewicht
=	×	×

Verdünnungsrechner Molekulargewichtsrechner

In vivo Charge:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Von Selleck Labs validiert. Sollten Sie Anpassungen an dieser Formulierung benötigen, kontaktieren Sie unser Verkaufsteam für kundenspezifische Tests.	10.000mg/ml (27.15mM)	Taking the 1 mL working solution as an example, add 50 μL of 200 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 10%PEG300 2 5%Tween80 3 80%ddH2O Von Selleck Labs validiert. Sollten Sie Anpassungen an dieser Formulierung benötigen, kontaktieren Sie unser Verkaufsteam für kundenspezifische Tests.	4.000mg/ml (10.86mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In-vivo-Formulierungsrechner (Klare Lösung)

Schritt 1: Geben Sie die untenstehenden Informationen ein (Empfohlen: Ein zusätzliches Tier zur Berücksichtigung von Verlusten während des Experiments)

Dosierung: mg/kg Durchschnittsgewicht der Tiere: g Dosiervolumen pro Tier:μL Anzahl der Tiere:

Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, keine Formulierung. Bitte kontaktieren Sie uns zuerst, wenn es im Abschnitt "Löslichkeit" keine In-vivo-Formulierung gibt.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Berechnungsergebnisse:

Arbeitskonzentration: mg/ml;

Methode zur Herstellung der DMSO-Stammlösung: mg Wirkstoff vorgelöst in μL DMSO ( Konzentration der Stammlösung mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der Wirkstoffcharge überschreitet. )

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügenμL PEG300, mischen und klären, dann hinzufügenμL Tween 80, mischen und klären, dann hinzufügen μL ddH₂O, mischen und klären.

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügen μL Maisöl, mischen und klären.

Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, das/die Lösungsmittel der Reihe nach hinzuzufügen. Sie müssen sicherstellen, dass die bei der vorherigen Zugabe erhaltene Lösung eine klare Lösung ist, bevor Sie mit der Zugabe des nächsten Lösungsmittels fortfahren. Physikalische Methoden wie Vortex, Ultraschall oder ein heißes Wasserbad können zur Unterstützung des Lösens verwendet werden.

Wirkmechanismus

Targets/IC₅₀/Ki	Nrf2 (Cell-free assay) Ferroptosis HDAC (Cell-free assay) NF-κB (Cell-free assay) p300 (Cell-free assay) ~25 μM
In vitro	Curcumin induziert die Expression des Forkhead-Box-Proteins O1 (FOXO1) durch Aktivierung der extrazellulären signalregulierten Kinase 1/2-Signalübertragung. Diese Verbindung hemmt die Zellproliferation, was mit der Hochregulierung der Cyclin-abhängigen Kinase-Inhibitoren p27 und p21 sowie der Herunterregulierung von Cyclin D1 verbunden war. Es induziert endoplasmatisches Retikulum (ER)-Stress und mitochondriale Dysfunktion, wie durch die Hochregulierung des CCAAT/Enhancer-bindenden Protein-homologen Proteins (CHOP), die Phosphorylierung von JNK und die Herunterregulierung von SERCA2ATPase, die Freisetzung von Cytochrom c, die Abnahme von Bcl-2 und die Reduzierung des mitochondrialen Membranpotentials in AGS- und HT-29-Zellen belegt wird.
In vivo	Chronische Behandlung mit Curcumin kehrt die CMS-induzierten Verhaltensauffälligkeiten bei gestressten Ratten signifikant um. Zusätzlich hemmt diese Verbindung effektiv die Zytokin-Genexpression sowohl auf mRNA- als auch auf Proteinebene und reduziert die Aktivierung von NF-κB.
Literatur	[1] https://pubmed.ncbi.nlm.nih.gov/23871787/ [2] https://pubmed.ncbi.nlm.nih.gov/23886126/ [3] https://pubmed.ncbi.nlm.nih.gov/23881281/ [4] https://pubmed.ncbi.nlm.nih.gov/23876788/ [5] https://pubmed.ncbi.nlm.nih.gov/15221965/ [6] https://pubmed.ncbi.nlm.nih.gov/15383533/ [7] https://pubmed.ncbi.nlm.nih.gov/17927689/ [8] https://pubmed.ncbi.nlm.nih.gov/7559628/ [9] https://pubmed.ncbi.nlm.nih.gov/31034781/

Anwendungen

Methoden	Biomarker	PMID
Western blot	p-IRE1α / IREα HDAC1/ HDAC2 p-STAT3 / STAT3	29901626
Immunofluorescence	β-catenin PKD1 EGFR / LC3	22523587
Growth inhibition assay	Cell proliferation Cell viability	22523587

Klinische Studieninformationen

(Daten von https://clinicaltrials.gov, aktualisiert am 2024-05-22)

NCT-Nummer	Rekrutierung	Erkrankungen	Sponsor/Kooperationspartner	Startdatum	Phasen
NCT06053411	Not yet recruiting	Interaction	Washington State University	January 1 2024	Early Phase 1
NCT05947513	Not yet recruiting	Cervical Cancer	Addis Ababa University\|Center for Innovative Drug Development and Therapeutic Trials for Africa Addis Ababa University\|Akay Natural Ingredients Private Limited	October 2023	Phase 1\|Phase 2
NCT05966441	Not yet recruiting	Chemotherapy-induced Peripheral Neuropathy	Ain Shams University	August 30 2023	Phase 2
NCT05774704	Recruiting	Bioavailability\|Gut Microbiome\|Safety	Texas Tech University Health Sciences Center	August 21 2023	Phase 1\|Phase 2

Technischer Support

Handhabungshinweise

Tel: +1-832-582-8158 Ext:3

Wenn Sie weitere Fragen haben, hinterlassen Sie bitte eine Nachricht.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):